PowerPoint Presentation · 2017-03-10 · • high risk groups for HCV transmission or exposure...
Transcript of PowerPoint Presentation · 2017-03-10 · • high risk groups for HCV transmission or exposure...
![Page 1: PowerPoint Presentation · 2017-03-10 · • high risk groups for HCV transmission or exposure (active injection drug users, ... SVR 13/15 (87%) F3 patients Welzel, EASL Conference](https://reader033.fdocuments.in/reader033/viewer/2022050509/5f9a4b56ecbeaa1a0821fe76/html5/thumbnails/1.jpg)
1392GR1700862-01 3/2017
![Page 2: PowerPoint Presentation · 2017-03-10 · • high risk groups for HCV transmission or exposure (active injection drug users, ... SVR 13/15 (87%) F3 patients Welzel, EASL Conference](https://reader033.fdocuments.in/reader033/viewer/2022050509/5f9a4b56ecbeaa1a0821fe76/html5/thumbnails/2.jpg)
1392GR1700862-01 3/2017
![Page 3: PowerPoint Presentation · 2017-03-10 · • high risk groups for HCV transmission or exposure (active injection drug users, ... SVR 13/15 (87%) F3 patients Welzel, EASL Conference](https://reader033.fdocuments.in/reader033/viewer/2022050509/5f9a4b56ecbeaa1a0821fe76/html5/thumbnails/3.jpg)
1392GR1700862-01 3/2017
![Page 4: PowerPoint Presentation · 2017-03-10 · • high risk groups for HCV transmission or exposure (active injection drug users, ... SVR 13/15 (87%) F3 patients Welzel, EASL Conference](https://reader033.fdocuments.in/reader033/viewer/2022050509/5f9a4b56ecbeaa1a0821fe76/html5/thumbnails/4.jpg)
UPDATE ON THE KEY
TREATMENT
GUIDELINES OVER
THE PAST YEAR
Nikolaos K. Gatselis
Department of Medicine
& Research Laboratory of Internal Medicine,
Larissa Medical School,
Thessaly University
1392GR1700862-01 3/2017
![Page 5: PowerPoint Presentation · 2017-03-10 · • high risk groups for HCV transmission or exposure (active injection drug users, ... SVR 13/15 (87%) F3 patients Welzel, EASL Conference](https://reader033.fdocuments.in/reader033/viewer/2022050509/5f9a4b56ecbeaa1a0821fe76/html5/thumbnails/5.jpg)
Disclosure
• Research Support: Gilead, Janssen, Bayern, Roche,
Abbvie, Regulus, MSD
• Speaker Bureau: BMS, ABBVIE
• Travel expenses: Janssen, BMS, Novartis, Gilead, TEVA,
Abbvie
5
![Page 6: PowerPoint Presentation · 2017-03-10 · • high risk groups for HCV transmission or exposure (active injection drug users, ... SVR 13/15 (87%) F3 patients Welzel, EASL Conference](https://reader033.fdocuments.in/reader033/viewer/2022050509/5f9a4b56ecbeaa1a0821fe76/html5/thumbnails/6.jpg)
![Page 7: PowerPoint Presentation · 2017-03-10 · • high risk groups for HCV transmission or exposure (active injection drug users, ... SVR 13/15 (87%) F3 patients Welzel, EASL Conference](https://reader033.fdocuments.in/reader033/viewer/2022050509/5f9a4b56ecbeaa1a0821fe76/html5/thumbnails/7.jpg)
Who should be treated?
All patients with chronic HCV infection are
candidates for antiviral treatment and
potentially be treated with the optimum
regimen which offers higher efficacy and better
safety and tolerability.
HASL 2017
![Page 8: PowerPoint Presentation · 2017-03-10 · • high risk groups for HCV transmission or exposure (active injection drug users, ... SVR 13/15 (87%) F3 patients Welzel, EASL Conference](https://reader033.fdocuments.in/reader033/viewer/2022050509/5f9a4b56ecbeaa1a0821fe76/html5/thumbnails/8.jpg)
Prioritization for administration
of DAAs • moderate fibrosis or cirrhosis (Ishak: 2-6, METAVIR F2-F4, Fibroscan >7.5
kPa)
• HCV recurrence after liver transplantation
• HIV co-infection or HBV-co-infection
• severe extrahepatic manifestations (cryoglobulinemia, B-cell NHL)
• chronic hemoglobinopathies with hepatic or non-hepatic complications due to chronic hemolysis
• hemophiliacs and patients with other hemostasis disorders
• chronic renal failure (regardless of hemodialysis)
• patients at risk of a rapid evolution of liver disease (immunosuppression or concurrent disease)
• contraindication for IFNα or ribavirin (regardless of liver fibrosis stage)
• high risk groups for HCV transmission or exposure (active injection drug users, multiple sexual partners)
HASL 2017
![Page 9: PowerPoint Presentation · 2017-03-10 · • high risk groups for HCV transmission or exposure (active injection drug users, ... SVR 13/15 (87%) F3 patients Welzel, EASL Conference](https://reader033.fdocuments.in/reader033/viewer/2022050509/5f9a4b56ecbeaa1a0821fe76/html5/thumbnails/9.jpg)
Greek authorities (11/2016)
• F3 – only treatment experienced
• F4 – naïve or treatment experienced
• Liver transplant recipients with HCV
recurrence
• Severe extra-hepatic manifestations (?)
![Page 10: PowerPoint Presentation · 2017-03-10 · • high risk groups for HCV transmission or exposure (active injection drug users, ... SVR 13/15 (87%) F3 patients Welzel, EASL Conference](https://reader033.fdocuments.in/reader033/viewer/2022050509/5f9a4b56ecbeaa1a0821fe76/html5/thumbnails/10.jpg)
DAAs Approved in 2014
![Page 11: PowerPoint Presentation · 2017-03-10 · • high risk groups for HCV transmission or exposure (active injection drug users, ... SVR 13/15 (87%) F3 patients Welzel, EASL Conference](https://reader033.fdocuments.in/reader033/viewer/2022050509/5f9a4b56ecbeaa1a0821fe76/html5/thumbnails/11.jpg)
DAAs Approved in 2015
![Page 12: PowerPoint Presentation · 2017-03-10 · • high risk groups for HCV transmission or exposure (active injection drug users, ... SVR 13/15 (87%) F3 patients Welzel, EASL Conference](https://reader033.fdocuments.in/reader033/viewer/2022050509/5f9a4b56ecbeaa1a0821fe76/html5/thumbnails/12.jpg)
DAAs Approved in 2016
![Page 13: PowerPoint Presentation · 2017-03-10 · • high risk groups for HCV transmission or exposure (active injection drug users, ... SVR 13/15 (87%) F3 patients Welzel, EASL Conference](https://reader033.fdocuments.in/reader033/viewer/2022050509/5f9a4b56ecbeaa1a0821fe76/html5/thumbnails/13.jpg)
HASL2017
Genotype 1a non-Cirrhotics Cirrhotics
naive exp naive exp
SOF+DCV 12w 12w 12w12w +RBV
24w
SOF/LDV 8w 12w 12w12w +RBV
24w
PRV/r/OBV+DSV 12w +RBV 12w +RBV 12w +RBV12w +RBV
24w +RBV (null-R)
SOF/VEL 12w 12w 12w 12w
EBR/GZR
12w (RAV- or HCVRNA ≤
800,000 IU/ml)16w +RBV (RAV+
or HCV RNA > 800,000 IU/ml
12w (RAV- or HCVRNA ≤
800,000 IU/ml)16w +RBV (RAV+
or HCV RNA > 800,000 IU/ml
12w (RAV- or HCVRNA ≤
800,000 IU/ml)16w +RBV (RAV+
or HCV RNA > 800,000 IU/ml
12w (RAV- or HCVRNA ≤
800,000 IU/ml)16w +RBV (RAV+
or HCV RNA > 800,000 IU/ml
![Page 14: PowerPoint Presentation · 2017-03-10 · • high risk groups for HCV transmission or exposure (active injection drug users, ... SVR 13/15 (87%) F3 patients Welzel, EASL Conference](https://reader033.fdocuments.in/reader033/viewer/2022050509/5f9a4b56ecbeaa1a0821fe76/html5/thumbnails/14.jpg)
EASL 2016
Genotype 1a non-Cirrhotics Cirrhotics
naive exp naive exp
SOF+DCV 12w12w +RBV
24w12w
12w +RBV24w
SOF/LDV 8-12w12w +RBV
24w12w
12w +RBV24w
PRV/r/OBV+DSV 12w +RBV 12w +RBV 24w +RBV 24w +RBV
SOF/VEL 12w 12w 12w 12w
EBR/GZR
12w (RAV- or HCVRNA ≤
800,000 IU/ml)16w +RBV (RAV+
or HCV RNA > 800,000 IU/ml
12w (RAV- or HCVRNA ≤
800,000 IU/ml)16w +RBV (RAV+
or HCV RNA > 800,000 IU/ml
12w (RAV- or HCVRNA ≤
800,000 IU/ml)16w +RBV (RAV+
or HCV RNA > 800,000 IU/ml
12w (RAV- or HCVRNA ≤
800,000 IU/ml)16w +RBV (RAV+
or HCV RNA > 800,000 IU/ml
![Page 15: PowerPoint Presentation · 2017-03-10 · • high risk groups for HCV transmission or exposure (active injection drug users, ... SVR 13/15 (87%) F3 patients Welzel, EASL Conference](https://reader033.fdocuments.in/reader033/viewer/2022050509/5f9a4b56ecbeaa1a0821fe76/html5/thumbnails/15.jpg)
AASLD2016
Genotype 1a non-Cirrhotics Cirrhotics
naive exp naive exp
SOF+DCV 12w 12w 24w ±RBV 24w ±RBV
SOF/LDV 12w 12w 12w12w +RBV
24w
PRV/r/OBV+DSV 12w +RBV 12w +RBV 24w +RBV 24w +RBV
SOF/VEL 12w 12w 12w 12w
EBR/GZR12w (RAV-)
16w +RBV (RAV+)12w (RAV-)
16w +RBV (RAV+)12w (RAV-)
16w +RBV (RAV+)12w (RAV-)
16w +RBV (RAV+)
![Page 16: PowerPoint Presentation · 2017-03-10 · • high risk groups for HCV transmission or exposure (active injection drug users, ... SVR 13/15 (87%) F3 patients Welzel, EASL Conference](https://reader033.fdocuments.in/reader033/viewer/2022050509/5f9a4b56ecbeaa1a0821fe76/html5/thumbnails/16.jpg)
HASL2017
Genotype 1b non-Cirrhotics Cirrhotics
naive exp naive exp
SOF+DCV 12w 12w 12w12w +RBV
24w
SOF/LDV 8w 12w 12w12w +RBV
24w
PRV/r/OBV+DSV 8w (?F3) 12w 12w 12w
SOF/VEL 12w 12w 12w 12w
EBR/GZR 12w 12w 12w 12w
![Page 17: PowerPoint Presentation · 2017-03-10 · • high risk groups for HCV transmission or exposure (active injection drug users, ... SVR 13/15 (87%) F3 patients Welzel, EASL Conference](https://reader033.fdocuments.in/reader033/viewer/2022050509/5f9a4b56ecbeaa1a0821fe76/html5/thumbnails/17.jpg)
EASL2016
Genotype 1b non-Cirrhotics Cirrhotics
naive exp naive exp
SOF+DCV 12w 12w 12w 12w
SOF/LDV 8-12w 12w 12w 12w
PRV/r/OBV+DSV 8-12w 12w 12w 12w
SOF/VEL 12w 12w 12w 12w
EBR/GZR 12w 12w 12w 12w
![Page 18: PowerPoint Presentation · 2017-03-10 · • high risk groups for HCV transmission or exposure (active injection drug users, ... SVR 13/15 (87%) F3 patients Welzel, EASL Conference](https://reader033.fdocuments.in/reader033/viewer/2022050509/5f9a4b56ecbeaa1a0821fe76/html5/thumbnails/18.jpg)
AASLD2016
Genotype 1b non-Cirrhotics Cirrhotics
naive exp naive exp
SOF+DCV 12w 12w 24w ±RBV 24w ±RBV
SOF/LDV 12w 12w 12w12w +RBV
24w
PRV/r/OBV+DSV 12w 12w 12w 12w
SOF/VEL 12w 12w 12w 12w
EBR/GZR 12w 12w 12w 12w
![Page 19: PowerPoint Presentation · 2017-03-10 · • high risk groups for HCV transmission or exposure (active injection drug users, ... SVR 13/15 (87%) F3 patients Welzel, EASL Conference](https://reader033.fdocuments.in/reader033/viewer/2022050509/5f9a4b56ecbeaa1a0821fe76/html5/thumbnails/19.jpg)
Genotype 1: SOF/VELASTRAL-1 Phase III, TN and TE (32%), Gt 1, 2, 4, 5, 6, 19% cirrhosis, 12wks
Feld, NEJM 2015
![Page 20: PowerPoint Presentation · 2017-03-10 · • high risk groups for HCV transmission or exposure (active injection drug users, ... SVR 13/15 (87%) F3 patients Welzel, EASL Conference](https://reader033.fdocuments.in/reader033/viewer/2022050509/5f9a4b56ecbeaa1a0821fe76/html5/thumbnails/20.jpg)
Genotype 1: GZR/EBRPooled efficacy population, G1a, Phase II and III trials, 12w, no RBV
![Page 21: PowerPoint Presentation · 2017-03-10 · • high risk groups for HCV transmission or exposure (active injection drug users, ... SVR 13/15 (87%) F3 patients Welzel, EASL Conference](https://reader033.fdocuments.in/reader033/viewer/2022050509/5f9a4b56ecbeaa1a0821fe76/html5/thumbnails/21.jpg)
Genotype 1: SOF/LDV
8w in naïve, non-Cirrhotics
![Page 22: PowerPoint Presentation · 2017-03-10 · • high risk groups for HCV transmission or exposure (active injection drug users, ... SVR 13/15 (87%) F3 patients Welzel, EASL Conference](https://reader033.fdocuments.in/reader033/viewer/2022050509/5f9a4b56ecbeaa1a0821fe76/html5/thumbnails/22.jpg)
Genotype 1b: PRV/r/OBV+DSV
8w in naïve w/o cirrhosis
GARNET study
Genotype 1bTreatment naïve
No cirrhosis F0-F3
SVR 13/15 (87%) F3 patients
Welzel, EASL Conference 2016
![Page 23: PowerPoint Presentation · 2017-03-10 · • high risk groups for HCV transmission or exposure (active injection drug users, ... SVR 13/15 (87%) F3 patients Welzel, EASL Conference](https://reader033.fdocuments.in/reader033/viewer/2022050509/5f9a4b56ecbeaa1a0821fe76/html5/thumbnails/23.jpg)
TURQUOISE-IISVR12 rate of 92-96% in 380 HCV GT-1 with Compensated
Cirrhosis treated with OBV/PTV/r + DSV + RBV
n=380, GT1a, GT1b, Cirrhosis (CP-A), TN, TE
Poordad, NEJM 2014
![Page 24: PowerPoint Presentation · 2017-03-10 · • high risk groups for HCV transmission or exposure (active injection drug users, ... SVR 13/15 (87%) F3 patients Welzel, EASL Conference](https://reader033.fdocuments.in/reader033/viewer/2022050509/5f9a4b56ecbeaa1a0821fe76/html5/thumbnails/24.jpg)
HASL2017
Genotype 2 non-Cirrhotics Cirrhotics
naive exp naive exp
SOF+RBV 12w - - -
SOF+DCV* 12w 12w 12w 12w
SOF/VEL 12w 12w 12w 12w
*limited data
![Page 25: PowerPoint Presentation · 2017-03-10 · • high risk groups for HCV transmission or exposure (active injection drug users, ... SVR 13/15 (87%) F3 patients Welzel, EASL Conference](https://reader033.fdocuments.in/reader033/viewer/2022050509/5f9a4b56ecbeaa1a0821fe76/html5/thumbnails/25.jpg)
Genotype 2: SOF/VELASTRAL 2 – Phase III, TN and TE (14%), Gt2, 14% cirrhosis, 12 w
Foster, NEJM 2015
![Page 26: PowerPoint Presentation · 2017-03-10 · • high risk groups for HCV transmission or exposure (active injection drug users, ... SVR 13/15 (87%) F3 patients Welzel, EASL Conference](https://reader033.fdocuments.in/reader033/viewer/2022050509/5f9a4b56ecbeaa1a0821fe76/html5/thumbnails/26.jpg)
EASL2016
Genotype 2 non-Cirrhotics Cirrhotics
naive exp naive exp
SOF+RBV - - -
SOF+DCV 12w 12w 12w 12w
SOF/VEL 12w 12w 12w 12w
![Page 27: PowerPoint Presentation · 2017-03-10 · • high risk groups for HCV transmission or exposure (active injection drug users, ... SVR 13/15 (87%) F3 patients Welzel, EASL Conference](https://reader033.fdocuments.in/reader033/viewer/2022050509/5f9a4b56ecbeaa1a0821fe76/html5/thumbnails/27.jpg)
AASLD2016
Genotype 2 non-Cirrhotics Cirrhotics
naive exp naive exp
SOF+RBV - - -
SOF+DCV 12w 12w 16-24w 16-24w
SOF/VEL 12w 12w 12w 12w
![Page 28: PowerPoint Presentation · 2017-03-10 · • high risk groups for HCV transmission or exposure (active injection drug users, ... SVR 13/15 (87%) F3 patients Welzel, EASL Conference](https://reader033.fdocuments.in/reader033/viewer/2022050509/5f9a4b56ecbeaa1a0821fe76/html5/thumbnails/28.jpg)
HASL2017
Genotype 3 non-Cirrhotics Cirrhotics
naive exp naive exp
SOF+DCV 12w 12w +RBV 12-24w +RBV 12-24w +RBV
SOF/VEL 12w 12w +RBV24w
12w +RBV24w
12w +RBV24w
![Page 29: PowerPoint Presentation · 2017-03-10 · • high risk groups for HCV transmission or exposure (active injection drug users, ... SVR 13/15 (87%) F3 patients Welzel, EASL Conference](https://reader033.fdocuments.in/reader033/viewer/2022050509/5f9a4b56ecbeaa1a0821fe76/html5/thumbnails/29.jpg)
EASL2016
Genotype 3 non-Cirrhotics Cirrhotics
naive exp naive exp
SOF+DCV 12w12w +RBV (RAV+)
24w (RAV+)24w +RBV 24w +RBV
SOF/VEL 12w 12w +RBV24w (RAV+)
12w +RBV24w
12w +RBV24w
![Page 30: PowerPoint Presentation · 2017-03-10 · • high risk groups for HCV transmission or exposure (active injection drug users, ... SVR 13/15 (87%) F3 patients Welzel, EASL Conference](https://reader033.fdocuments.in/reader033/viewer/2022050509/5f9a4b56ecbeaa1a0821fe76/html5/thumbnails/30.jpg)
AASLD2016
Genotype 3 non-Cirrhotics Cirrhotics
naive exp naive exp
SOF+DCV 12w 12w 24w ±RBV 24w +RBV
SOF/VEL 12w12w 12w 12w +RBV
![Page 31: PowerPoint Presentation · 2017-03-10 · • high risk groups for HCV transmission or exposure (active injection drug users, ... SVR 13/15 (87%) F3 patients Welzel, EASL Conference](https://reader033.fdocuments.in/reader033/viewer/2022050509/5f9a4b56ecbeaa1a0821fe76/html5/thumbnails/31.jpg)
Genotype 3: SOF + DCVALLY-3 – Phase III, TN and TE, Gt3, F0-F4, 12 w
Nelson, Hepatology 2015
![Page 32: PowerPoint Presentation · 2017-03-10 · • high risk groups for HCV transmission or exposure (active injection drug users, ... SVR 13/15 (87%) F3 patients Welzel, EASL Conference](https://reader033.fdocuments.in/reader033/viewer/2022050509/5f9a4b56ecbeaa1a0821fe76/html5/thumbnails/32.jpg)
Genotype 3: SOF + DCV +RBV• ALLY-3+: SVR12 by Cirrhosis Status
Leroy, Hepatology 2016
ALLY-3+, Phase III, TN and TE, Gt3, F3F4, 12-16 w
![Page 33: PowerPoint Presentation · 2017-03-10 · • high risk groups for HCV transmission or exposure (active injection drug users, ... SVR 13/15 (87%) F3 patients Welzel, EASL Conference](https://reader033.fdocuments.in/reader033/viewer/2022050509/5f9a4b56ecbeaa1a0821fe76/html5/thumbnails/33.jpg)
Genotype 3: SOF/VELASTRAL 3 – Phase III, TN and TE, Gt3, F0-F4, 12 w
Foster, NEJM 2015
![Page 34: PowerPoint Presentation · 2017-03-10 · • high risk groups for HCV transmission or exposure (active injection drug users, ... SVR 13/15 (87%) F3 patients Welzel, EASL Conference](https://reader033.fdocuments.in/reader033/viewer/2022050509/5f9a4b56ecbeaa1a0821fe76/html5/thumbnails/34.jpg)
HASL2017
Genotype 4 non-Cirrhotics Cirrhotics
naive exp naive exp
SOF+DCV 12w12w +RBV
24w12w
12w +RBV24w
SOF/LDV 12w12w +RBV
24w12w
12w +RBV24w
PRV/r/OBV 12w +RBV 12w +RBV 12w +RBV 12w +RBV
SOF/VEL 12w 12w 12w 12w
EBR/GZR 12w
12w (HCV RNA≤800,000
IU/ml)16w +RBV (HCV RNA>800,000
IU/ml)
12w
12w (HCV RNA≤800,000
IU/ml)16w +RBV (HCV RNA>800,000
IU/ml)
*limited data
*limited data
*limited data
![Page 35: PowerPoint Presentation · 2017-03-10 · • high risk groups for HCV transmission or exposure (active injection drug users, ... SVR 13/15 (87%) F3 patients Welzel, EASL Conference](https://reader033.fdocuments.in/reader033/viewer/2022050509/5f9a4b56ecbeaa1a0821fe76/html5/thumbnails/35.jpg)
ΕASL2016
Genotype 4 non-Cirrhotics Cirrhotics
naive exp naive exp
SOF+DCV 12w12w +RBV
24w12w
12w +RBV24w
SOF/LDV 12w12w +RBV
24w12w
12w +RBV24w
PRV/r/OBV 12w +RBV 12w +RBV 12w +RBV 12w +RBV
SOF/VEL 12w 12w 12w 12w
EBR/GZR 12w
12w (HCV RNA≤800,000
IU/ml)16w +RBV (HCV RNA>800,000
IU/ml)
12w
12w (HCV RNA≤800,000
IU/ml)16w +RBV (HCV RNA>800,000
IU/ml)
![Page 36: PowerPoint Presentation · 2017-03-10 · • high risk groups for HCV transmission or exposure (active injection drug users, ... SVR 13/15 (87%) F3 patients Welzel, EASL Conference](https://reader033.fdocuments.in/reader033/viewer/2022050509/5f9a4b56ecbeaa1a0821fe76/html5/thumbnails/36.jpg)
AASLD2016
Genotype 4 non-Cirrhotics Cirrhotics
naive exp naive exp
SOF+DCV
SOF/LDV 12w 12w 12w12w +RBV
24w
PRV/r/OBV 12w +RBV 12w +RBV 12w +RBV 12w +RBV
SOF/VEL 12w 12w 12w 12w
EBR/GZR 12w
12w (relapsers)16w +RBV (on-
treatment failures)
12w
12w (relapsers)16w +RBV (on-
treatment failures)
![Page 37: PowerPoint Presentation · 2017-03-10 · • high risk groups for HCV transmission or exposure (active injection drug users, ... SVR 13/15 (87%) F3 patients Welzel, EASL Conference](https://reader033.fdocuments.in/reader033/viewer/2022050509/5f9a4b56ecbeaa1a0821fe76/html5/thumbnails/37.jpg)
Genotype 4: SOF/VELASTRAL 1 – Phase III, TN and TE (32%), Gt4, 19% cirrhosis, 12 w
Feld, NEJM 2015
100%
0
25
50
75
100
GT4N=116
SVR
12
rat
e (
%)
![Page 38: PowerPoint Presentation · 2017-03-10 · • high risk groups for HCV transmission or exposure (active injection drug users, ... SVR 13/15 (87%) F3 patients Welzel, EASL Conference](https://reader033.fdocuments.in/reader033/viewer/2022050509/5f9a4b56ecbeaa1a0821fe76/html5/thumbnails/38.jpg)
Genotype 4: OBV/PTV/r +RBV
Asselah, Lancet Gastroenterol Hepatol 2016Waked, Lancet Gastroenterol Hepatol 2016
![Page 39: PowerPoint Presentation · 2017-03-10 · • high risk groups for HCV transmission or exposure (active injection drug users, ... SVR 13/15 (87%) F3 patients Welzel, EASL Conference](https://reader033.fdocuments.in/reader033/viewer/2022050509/5f9a4b56ecbeaa1a0821fe76/html5/thumbnails/39.jpg)
Genotype 4: GRZ/EBRIntegrated analysis of Phase II and III trials, Gt4, w/o cirrhosis
Asselah, AASLD 2015
![Page 40: PowerPoint Presentation · 2017-03-10 · • high risk groups for HCV transmission or exposure (active injection drug users, ... SVR 13/15 (87%) F3 patients Welzel, EASL Conference](https://reader033.fdocuments.in/reader033/viewer/2022050509/5f9a4b56ecbeaa1a0821fe76/html5/thumbnails/40.jpg)
HASL2017
Genotype 5,6
non-Cirrhotics Cirrhotics
naive exp naive exp
SOF/LDV 12w 12w +RBV 12w 12w +RBV
SOF/VEL 12w 12w 12w 12w
![Page 41: PowerPoint Presentation · 2017-03-10 · • high risk groups for HCV transmission or exposure (active injection drug users, ... SVR 13/15 (87%) F3 patients Welzel, EASL Conference](https://reader033.fdocuments.in/reader033/viewer/2022050509/5f9a4b56ecbeaa1a0821fe76/html5/thumbnails/41.jpg)
Monitoring Patients
Prior
• FBC, INR, LFTs, eGFR• HCV genotype• HCV RNA• Fibrosis stage• DDIs• Pregnancy• *RAVs testing
During• FBC every 2-4weeks (RBV)• ALT every 4 weeks• HCV RNA (EOT in non-adherence or DAAs failure)
Post• HCV RNA (SVR12) (48w)• US every 6 months in F4
![Page 42: PowerPoint Presentation · 2017-03-10 · • high risk groups for HCV transmission or exposure (active injection drug users, ... SVR 13/15 (87%) F3 patients Welzel, EASL Conference](https://reader033.fdocuments.in/reader033/viewer/2022050509/5f9a4b56ecbeaa1a0821fe76/html5/thumbnails/42.jpg)
Conclusions
• HCV is the only curable chronic viral infection
• Extension of priorities for access to DAAs
• Predominance of IFN-free regimens
• Simplification of treatment regimens
– shorter duration (<12 weeks)
– without ribavirin
• Testing for HCV RAVs should not be a barrier to treatment
• Treatment individualization
![Page 43: PowerPoint Presentation · 2017-03-10 · • high risk groups for HCV transmission or exposure (active injection drug users, ... SVR 13/15 (87%) F3 patients Welzel, EASL Conference](https://reader033.fdocuments.in/reader033/viewer/2022050509/5f9a4b56ecbeaa1a0821fe76/html5/thumbnails/43.jpg)
Thank you for your attention!